|
Age (years, median and IQR)
|
≥ 18
|
62.5 (51.3–71)
|
59.2 (50.2–71)
|
69.4 (60.2–71.7)
|
|
Sex (female, n and %)
| |
9 (23.1)
|
7 (22.6)
|
2 (25)
|
|
BMI > 25 kg/m2 (n and %)
| |
27 (69.2)
|
21 (67.7)
|
6 (75)
|
|
Active smokers (n and %)
| |
3 (7.7)
|
2 (6.4)
|
1 (12.5)
|
|
Previous smokers (n and %)
| |
12 (30.8)
|
8 (25.8)
|
4 (50)
|
|
Smoking burden (p/y, mean ± SD)
| |
10.4 ± 16.6
|
7.8 ± 14.9
|
20.7 ± 19.9
|
|
Allergies (n and %)
| |
11 (28.2)
|
9 (29)
|
2 (33.3)
|
|
Flu vaccination on adm. (n and %)
| |
12 (30.8)
|
9 (29)
|
4 (50)
|
|
Pneumococcal vaccination on adm. (n and %)
| |
1 (2.6)
|
0 (0)
|
1 (12.5)
|
|
Length of stay (days, median and IQR)
| |
15 (12–22)
|
15 (11–21)
|
15.5 (12–28.7)
|
|
Hypertension (n and %)
| |
11 (28.2)
|
9 (29)
|
5 (62.5)
|
|
Diabetes (n and %)
| |
5 (12.8)
|
4 (12.9)
|
1 (12.5)
|
|
Cardiovascular diseases (n and %)
| |
7 (17.9)
|
5 (16.1)
|
2 (33.3)
|
|
Coronary heart disease (n and %)
| |
4 (10.2)
|
2 (6.4)
|
2 (33.3)
|
|
Chronic respiratory diseases (n and %)
| |
8 (20.5)
|
6 (19.4)
|
2 (33.3)
|
|
COPD (n and %)
| |
3 (7.7)
|
2 (6.4)
|
1 (12.5)
|
|
Asthma (n and %)
| |
5 (12.8)
|
4 (12.9)
|
1 (12.5)
|
|
Chronic kidney disease (n and %)
| |
3 (7.7)
|
2 (6.4)
|
1 (12.5)
|
|
Malignancy (n and %)
| |
4 (10.2)
|
3 (9.7)
|
1 (12.5)
|
|
Intensive care unit admission (n and %)
| |
10 (25.6)
|
9 (29)
|
1 (12.5)
|
|
Invasive mechanical ventilation (n and %)
| |
7 (17.9)
|
6 (19.4)
|
1 (12.5)
|
|
Rehab. after discharge (n and %)
| |
7 (17.9)
|
6 (19.4)
|
1 (12.5)
|
|
Peak PCR (mg/l) (mean ± SD)
|
1–5
|
185.7 ± 147.4
|
178.5 ± 137.4
|
213.4 ± 189.6
|
|
Peak LDH (U/l) (mean ± SD)
|
< 500
|
653.2 ± 348.5
|
693.4 ± 364.8
|
502.4 ± 240.3
|
|
Peak leukocytes (G/l) (mean ± SD)
|
4.2–10
|
8.9 ± 4.8
|
8.3 ± 3.8
|
11.1 ± 7.5
|
|
Peak lymphopenia (G/l) (mean ± SD)
|
1.5 – 2.5
|
0.7 ± 0.2
|
0.7 ± 0.2
|
0.6 ± 0.3
|
|
Peak thrombopenia (G/l) (mean ± SD)
|
150–400
|
185.5 ± 81.9
|
187.6 ± 72.6
|
177 ± 117
|
|
Peak d-dimer (mg/l) (mean ± SD)
|
< 0.5
|
4.8 ± 10
|
5.3 ± 11.5
|
2.9 ± 2.9
|
|
Lympho. on adm. (G/l) (mean ± SD)
|
1.5–2.5
|
0.8 ± 0.3
|
0.9 ± 0.3
|
0.67 ± 0.3
|
|
Leuko. on adm. (G/l) (mean ± SD)
|
4.2–10
|
5.5 ± 2.3
|
5.5 ± 2.3
|
5.5 ± 2.4
|
|
Thrombo on adm. (G/l) (mean ± SD)
|
150–400
|
189.9 ± 74.7
|
190 ± 64.2
|
189.4 ± 112.4
|
|
PaO2 on adm. (kPa) (mean ± SD)
|
> 8
|
9.3 ± 1.4
|
9.3 ± 1.5
|
9.2 ± 0.6
|
|
nt-proBNP on adm. (ng/l) (mean ± SD)
|
< 450
|
275.7 ± 253.7
|
229.5 ± 219.3
|
488 ± 318.4
|
|
D-dimer (mg/l) (mean ± SD)
|
< 0.5
|
1.1 ± 0.8
|
1.2 ± 0.9
|
0.9 ± 0.6
|
|
Antibiotics (n and %)
| |
24 (61.5)
|
21 (67.7)
|
8 (37.5)
|
|
Hydroxychloroquine (n and %)
| |
32 (82)
|
24 (77.4)
|
8 (100)
|
|
Remdesevir (n and %)
| |
2 (5.1)
|
2 (6.4)
|
0 (0)
|
|
Tocilizumab (n and %)
| |
4 (10.2)
|
4 (12.9)
|
0 (0)
|
|
Lopinavir-Ritonavir (n and %)
| |
21 (53.8)
|
19 (61.3)
|
2 (25)
|
|
ACE-I, ARB treatment (n and %)
| |
11 (28.2)
|
8 (25.8)
|
3 (37.5)
|
|
Anticoag. on adm. (n and %)
| |
4 (10.2)
|
2 (6.4)
|
2 (25)
|
|
Antiplt. on adm. (n and %)
| |
7 (17.9)
|
6 (19.4)
|
1 (12.5)
|
|
GGO on adm (n and %)
| |
34 (89.5)
|
27 (87.1)
|
7 (87.5)
|
|
Consolidations on adm (n and %)
| |
17 (43.6)
|
15 (48.4)
|
2 (25)
|
|
Fibrous bands on adm (n and %)
| |
28 (71.8)
|
22 (71)
|
6 (75)
|
